Abstract:ABSTRACT Shigella flexneri is a facultative intracellular pathogen that causes shigellosis, a human diarrheal disease characterized by the destruction of the colonic epithelium. Novel antimicrobial compounds to treat infections are urgently needed due to the proliferation of bacterial antibiotic resistance and lack of new effective antimicrobials in the market. Our approach to find compounds that block the Shigella virulence pathway has three potential advantages: (i) resistance development should be minimized due to the lack of growth selection pressure, (ii) no resistance due to environmental antibiotic exposure should be developed since the virulence pathways are not activated outside of host infection, and (iii) the normal intestinal microbiota, which do not have the targeted virulence pathways, should be unharmed. We chose to utilize two phenotypic assays, inhibition of Shigella survival in macrophages and Shigella growth inhibition (minimum inhibitory concentration), to interrogate the 1.7 M compound screening collection subset of the GlaxoSmithKline drug discovery chemical library. A number of secondary assays on the hit compounds resulting from the primary screens were conducted, which, in combination with chemical, structural, and physical property analyses, narrowed the final hit list to 44 promising compounds for further drug discovery efforts. IMPORTANCE The rapid development of antibiotic resistance is a critical problem that has the potential of returning the world to a “pre-antibiotic” type of environment, where millions of people will die from previously treatable infections. One relatively newer approach to minimize the selection pressures for the development of resistance is to target virulence pathways. This is anticipated to eliminate any resistance selection pressure in environmental exposure to virulence-targeted antibiotics and will have the added benefit of not affecting the non-virulent microbiome. This paper describes the development and application of a simple, reproducible, and sensitive assay to interrogate an extensive chemical library in high-throughput screening format for activity against the survival of Shigella flexneri 2457T-nl in THP-1 macrophages. The ability to screen very large numbers of compounds in a reasonable time frame (~1.7 M compounds in ~8 months) distinguishes this assay as a powerful tool in further exploring new compounds with intracellular effect on S. flexneri or other pathogens with similar pathways of pathogenesis. The assay utilizes a luciferase reporter which is extremely rapid, simple, relatively inexpensive, and sensitive and possesses a broad linear range. The assay also utilized THP-1 cells that resemble primary monocytes and macrophages in morphology and differentiation properties. THP-1 cells have advantages over human primary monocytes or macrophages because they are highly plastic and their homogeneous genetic background minimizes the degree of variability in the cell phenotype ( 1 ). The intracellular and virulence-targeted selectivity of our methodology, determined via secondary screening, is an enormous advantage. Our main interest focuses on hits that are targeting virulence, and the most promising compounds with adequate physicochemical and drug metabolism and pharmacokinetic (DMPK) properties will be progressed to a suitable in vivo shigellosis model to evaluate the therapeutic potential of this approach. Additionally, compounds that act via a host-directed mechanism could be a promising source for further research given that it would allow a whole new, specific, and controlled approach to the treatment of diseases caused by some pathogenic bacteria.

An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs

Using C. elegans Forward and Reverse Genetics to Identify New Compounds with Anthelmintic Activity

Applications of Caenorhabditis elegans in drug screening

An Extensive Comparison of the Effect of Anthelmintic Classes on Diverse Nematodes

An Efficient and Novel Screening Model for Assessing the Bioactivity of Extracts Against Multidrug-Resistant Pseudomonas Aeruginosa Using Caenorhabditis Elegans.

Effective drug combination for Caenorhabditis elegans nematodes discovered by output-driven feedback system control technique

Structure activity relationship and target prediction for ABX464 analogues in Caenorhabditis elegans

Using Caenorhabditis elegans to Model Therapeutic Interventions of Neurodegenerative Diseases Targeting Microbe-Host Interactions

A microfluidic device for whole-animal drug screening using electrophysiological measures in the nematode C. elegans

Caenorhabditis elegans as in vivo model for the screening of natural plants-derived novel anti-aging compounds: a short introduction

Diving into drug-screening: Zebrafish Embryos as an in vivo Platform for Antimicrobial Drug Discovery and Assessment

Preliminary Acute Toxicity Assessment of Pharmaceutical Compounds by Caenorhabditis Elegans

A drug discovery pipeline for MAPK/ERK pathway inhibitors in C. elegans

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology

Novel inhibitors that target bacterial virulence identified via HTS against intra-macrophage survival of Shigella flexneri

Application of 3Rs in Caenorhabditis elegans Research for the Identification of Health-Promoting Natural Products

Model organism C.elegans applications in the complex-system drug activity evaluation

High-throughput screening of more than 30,000 compounds for anthelmintics against gastrointestinal nematode parasites

A high-throughput phenotypic screen combined with an ultra-large-scale deep learning-based virtual screening reveals novel scaffolds of antibacterial compounds

Caenorhabditis elegans as a Model Host to Monitor the Candida Infection Processes

Caenorhabditis elegans as a powerful alternative model organism to promote research in genetic toxicology and biomedicine